Oxford Biomedica initiated with a Buy at Jefferies

Jefferies analyst James Vane-Tempest initiated coverage of Oxford Biomedica (OXBDF) with a Buy rating and 566 GBp price target Despite its strong track record of excellence, commercial experience, and other key metrics for customers, Oxford shares have weakened year-to-date, the analyst tells investors in a research note. While shares offer upside should guidance be achieved, there is limited visibility in an uncertain market, Jefferies added.